# Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

> **NCT04854746** · PHASE1 · COMPLETED · sponsor: **Vaxart** · enrollment: 66 (actual)

## Conditions studied

- Norovirus Infections

## Interventions

- **BIOLOGICAL:** VXA-GI.1.NN
- **BIOLOGICAL:** Placebo Tablet

## Key facts

- **NCT ID:** NCT04854746
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-26
- **Primary completion:** 2022-01-04
- **Final completion:** 2022-01-04
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04854746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04854746, "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04854746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*